"Company anticipated EBITDA growth to exceed sales growth in FY2017 and NPAT would be higher than $69.3 million (pre-implementation costs)"
"Company now anticipates FY2017 NPAT (pre implementation costs and significant items set out below) to be between $66 million and $70 million."
Not much difference at all. The significant items below the line are the write down on sass and bide and topshop which are non-cash charges. So really this is a very small re-guidance. I wouldn't say downgrade as the guidance states $66m to $70m. Non-cash charges are non-recurring so they can minimise tax payable by writing down the two brands. Overselling today but will bounce back. Average for me is quite low and i've been offset with Santos today which is a positive.
- Forums
- ASX - By Stock
- Ann: Myer Update
MYR
myer holdings limited
Add to My Watchlist
0.83%
!
60.0¢

"Company anticipated EBITDA growth to exceed sales growth in...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
60.0¢ |
Change
-0.005(0.83%) |
Mkt cap ! $1.036B |
Open | High | Low | Value | Volume |
61.0¢ | 61.5¢ | 59.5¢ | $5.633M | 9.346M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 106983 | 59.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
60.5¢ | 111282 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 0.610 |
3 | 3145 | 0.600 |
6 | 47783 | 0.595 |
18 | 108821 | 0.590 |
11 | 148279 | 0.585 |
Price($) | Vol. | No. |
---|---|---|
0.600 | 42067 | 2 |
0.605 | 51282 | 1 |
0.610 | 51867 | 5 |
0.615 | 78299 | 5 |
0.620 | 72226 | 7 |
Last trade - 16.11pm 25/06/2025 (20 minute delay) ? |
Featured News
MYR (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online